Jennifer Gonzalez, MD
Geriatric Medicine · East Setauket, NYNPI 1497853840
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.0% of the total across 70 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 24 manufacturers reported payments, led by Amgen at 24.5% of the total. 2025 is the largest year on record at $539, more than ten times the $37 reported in 2019.
Across 70 payments — averaging $33.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$580
- Novartis$254
- Lilly USA, LLC$157
- Novo Nordisk$148
- GSK$141
- Exact Sciences$137
- plus $954 from 18 others
What the payments were for
- Food & beverage$2,34699%
- Education$231%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 13 | $580 |
| Novartis | 10 | $254 |
| Lilly USA, LLC | 7 | $157 |
| Novo Nordisk | 3 | $148 |
| GSK | 2 | $141 |
| Exact Sciences | 5 | $137 |
| Pfizer | 5 | $127 |
| Regeneron Healthcare Solutions, Inc. | 1 | $125 |
| Esperion Therapeutics, Inc. | 1 | $125 |
| Idorsia Pharmaceuticals US Inc | 5 | $118 |
| Sanofi-aventis U.S. LLC | 1 | $94 |
| Inspire Medical Systems, Inc. | 2 | $70 |
| Astellas Pharma US Inc | 2 | $46 |
| Currax Pharmaceuticals LLC | 2 | $34 |
| AstraZeneca(2 entities) | 2 | $32 |
| Daiichi Sankyo Inc. | 1 | $28 |
| Boehringer Ingelheim | 1 | $24 |
| Amarin Pharma, Inc. | 1 | $21 |
| Sumitomo Pharma America, Inc. | 1 | $20 |
| Teva Pharmaceuticals USA, Inc. | 1 | $19 |
| Bayer | 1 | $19 |
| Lundbeck LLC | 1 | $18 |
| AbbVie | 1 | $18 |
| Eisai Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,369 in reported general payments places this provider in the 85th percentile of 400 geriatric medicine providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 131 | $190,312 |
| OzempicSemaglutide | 68 | $91,907 |
| JardianceEmpagliflozin | 41 | $53,259 |
| XareltoRivaroxaban | 30 | $42,668 |
| MounjaroTirzepatide | 35 | $42,055 |
| JanuviaSitagliptin Phosphate | 28 | $30,108 |
| MyrbetriqMirabegron | 23 | $21,915 |
| TradjentaLinagliptin | 16 | $12,126 |
| SymbicortBudesonide/Formoterol Fumarate | 18 | $9,104 |
| VascepaIcosapent Ethyl | 11 | $7,711 |
| Metoprolol Succinate | 390 | $7,586 |
| Atorvastatin Calcium | 597 | $6,223 |
| Levothyroxine Sodium | 380 | $5,696 |
| Ezetimibe | 148 | $5,474 |
| Rosuvastatin Calcium | 438 | $5,270 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $127 | $190,312131 claims |
| Novo NordiskOzempic | $148 | $91,90768 claims |
| Boehringer IngelheimJardiance, Tradjenta | $24 | $65,38457 claims |
| Lilly USA, LLCMounjaro | $157 | $42,05535 claims |
| Astellas Pharma US IncMyrbetriq | $46 | $21,91523 claims |
| AstraZenecaSymbicort | $32 | $9,10418 claims |
| AbbVieSynthroid | $18 | $5,027100 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 400 geriatric medicine providers in New York.
Other geriatric medicine in East Setauket
- Lovedhi AggarwalEast Setauket$2K
- Wen DombrowskiBrooklyn$45K
- Sharon BrangmanSyracuse$45K
- Howard FillitNew York$42K
- Adam CohenGreat Neck$27K
- Inna ShifrinBrooklyn$21K
- Amit SaxenaBronx$16K
- Nirmala TummalapentaBronx$16K
- Nasem SayeghElmsford$15K
- Bruce LowellGreat Neck$14K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.